Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s significant presence at the 40th ECTRIMS Congress in Copenhagen. Muehler emphasised the importance of this event for Immunic, particularly with vidofludimus calcium, its promising treatment for multiple sclerosis (MS).
This year marked a milestone for Immunic as it had its own booth for the first time, garnering substantial attention. Muehler detailed the four posters presented, including data from the Phase 2 CALLIPER trial for progressive MS and the drug's potential effect on neuroprotection and MS fatigue. One key area of focus was the potential impact of vidofludimus calcium on MS fatigue, a symptom that severely affects over half of MS patients.
He also highlighted the broader relevance of vidofludimus calcium's antiviral properties and its potential effect on EBV reactivation, a known contributor to fatigue. The enthusiasm for Immunic’s ongoing Phase 3 and Phase 2 trials shows the company’s commitment to addressing unmet needs in MS treatment. With crucial milestones like the CALLIPER trial readout scheduled for April 2025, Immunic continues to play a significant role in advancing MS research.
For more interviews and updates on the latest in biotech and pharmaceuticals, be sure to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for future content.
#Immunic #MultipleSclerosis #ECTRIMS2024 #VidofludimusCalcium #MSFatigue #Phase3Trials #Biotech #Neuroprotection #MSResearch #EBV #MSAwareness #CALLIPERtrial #ProgressiveMS
#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
